Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 47

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 47
---
 any benefits under, a non-qualified deferred compensation plan sponsored by us during the fiscal year ended December 31, 2024. Agreements with Our Named Executive Officers Offer Letters Below are descriptions of our offer letters with our named executive officers. For a discussion of the severance pay and other benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see the section titled “Potential Payments Upon Termination or Change of Control” below. Dr. Fordyce . In December 2020, we and Dr. Fordyce entered into an offer letter setting forth the initial terms of Dr. Fordyce’s employment with us, which was amended and restated in May 2021. Dr. Fordyce is entitled to certain severance benefits pursuant to such offer letter, as amended and restated, the terms of which are described below under the section titled “Potential Payments Upon Termination or Change of Control.” Dr. Fordyce’s employment is at will.

31

TABLE OF CONTENTS

Mr. Carter . In November 2024, we and Mr. Carter entered into an offer letter setting forth the initial terms of Mr. Carter’s employment with us. Pursuant to his offer letter, Mr. Carter received a sign-on bonus, the terms of which are described above in the section titled “Summary Compensation Table,” as well as an initial equity grant of 53,000 RSUs and an option to purchase 108,000 shares of the Company’s Class A common stock. Mr. Carter is also entitled to certain severance benefits pursuant to such offer letter, the terms of which are described below under the section titled “Potential Payments Upon Termination or Change of Control.” Mr. Carter’s employment is at will. Dr. Brenner . In January 2024, we and Dr. Brenner entered into an offer letter setting forth the initial terms of Dr. Brenner’s employment with us. Pursuant to his offer letter, Dr. Brenner received a sign-on bonus, the terms of which are described above in the section titled “Summary Compensation Table,” as well as an initial equity grant of an option to purchase 350,000 shares of the Company’s Class A common stock. Dr. Brenner is also entitled to certain severance benefits pursuant to such offer letter, the terms of which are described below under the section title “Potential Payments Upon Termination or Change of Control.” Dr. Brenner’s employment is at-will